Early Changes of Serum Interleukin 14α Levels Predicts the Response to Anti-PD-1 Therapy in Cancer

BACKGROUND: Programmed cell death-1 (PD-1) blockade has been shown to confer clinical benefit in cancer patients. Here, we assessed the level of serum interleukin 14α (IL14α) in patients receiving anti-PD-1 treatment. METHODS: This prospective study recruited 30 patients with advanced solid cancer w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Buhai, Chen, Caiyue, Jiang, Shiyu, Huang, Yuxiang, Zeng, Yichun, Li, Lei, Wang, Maoqi, Guo, Jingliang, Li, Qiuxian, Cao, Jin, Shen, Long, Gu, Juan J, Liang, Yichen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123909/
https://www.ncbi.nlm.nih.gov/pubmed/37101524
http://dx.doi.org/10.1177/11795549231163369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123909/
https://www.ncbi.nlm.nih.gov/pubmed/37101524
http://dx.doi.org/10.1177/11795549231163369

Ejemplares similares